Ramsey Crookall Chooses Objectway as a Strategic Partner for Digital Transformation and Market Expansion
Objectway, global FinTech provider of as-a-service software to banks, wealth and asset managers, has been working with Ramsey Crookall to progressively support the firm’s organic business growth and expansion into other areas of the market over recent years.
Ramsey Crookall is the Isle of Man’s longest established independent stockbroking and award-winning investment firm, providing a full range of bespoke stockbroking and wealth management services to private and institutional clients, trusts and pension funds predominantly in the UK, the Isle of Man and South Africa.
Its partnership with Objectway has enabled Ramsey Crookall to evolve from a traditional values stockbroker to a progressive, digitally-enabled multi-service investment management firm. This evolution has been supported by Objectway’s modular solution providing the firm with a scalable front-to-back technology platform.
This long-term strategic collaboration began with the provision of Objectway’s Investment Administration, enabling the firm to streamline and manage the core back-office operations more efficiently, whilst freeing up resources to deliver scale and enabling them to differentiate their business in the market.
In the second phase, Objectway’s Portfolio Management enhanced the firm’s ability to deliver efficient management and execution of their investment strategy for their Investment Managers and Dealers.
In a third phase, Objectway integrated these capabilities with the new client portal to enable an omni-channel and streamlined digital investment experience for Ramsey’s clients. This improved client visibility and significantly digitalised their client touch points without losing the personal touch that their business has so successfully built throughout its long history.
The current phase is to introduce enhanced capabilities for client lifecycle management, a more efficient client onboarding process and client Apps to provide clients with the choice for even greater flexibility and digital interaction, by deploying Objectway’s Client Management solutions.
“As a trusted family business offering a bespoke service, we’re constantly evolving to meet our clients’ needs and expectations. As such, we wanted to rely on a partner who shared the same future-focused vision, who could enable a steady technology evolution for the business,” said Joanna Crookall, CEO at Ramsey Crookall. “Our long-standing relationship with Objectway has enabled us to expand our services seamlessly into new territories, such as South Africa and to develop new services, such as, our discretionary model service aimed at the next generation of investors and our trading/custody services for professional clients. Over the years we have valued their ability to support our business differentiation and expansion at a pace that suited us.”
“We’re proud to have been partnering with Ramsey Crookall contributing to their success. By moving entirely to our SaaS solution, we’ve been able to meet their objectives for efficiency, cost effectiveness, scalability and timely delivery. Ramsey Crookall appreciated the value and benefits of a fully integrated, fully managed and digitally enabled solution from a single, trusted partner. We look forward to delivering value to their business for many years to come” commented Alexander Cassar, Objectway’sChief Business Development Officer.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515189528/en/
Contact information
Chiara Giudici
+393938229579
chiara.giudici@objectway.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press Release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press Release
ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors (corner cube prisms) designed to reflect laser beams directly back to their source, regardless of the an
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press Release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results23.12.2024 18:43:00 CET | Press Release
Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024. "Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income attributable to common stock of $1.8 million in the nine months ended October 31, 2023,” noted President and CEO David Mansfield. “Backlog in the third quarter shows considerable growth and now stands at $114.2 million. This is the equivalent to approximately nine months revenue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom